RxDoctor Payments Data

Aziz Mohiuddin, MD

Psychiatry · Columbia, SCNPI 1982678660

Payments from drug & device makers

$1,598in general payments, 2019–2025

Across 105 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$399
  • Neurocrine Biosciences, Inc.$302
  • Otsuka America Pharmaceutical, Inc.$287
  • Takeda Pharmaceuticals U.S.A., Inc.$180
  • Johnson & Johnson$136
  • Avanir Pharmaceuticals, Inc.$78
  • plus $215 from 8 others

What the payments were for

  • Food & beverage$1,56898%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,598 in reported general payments places this provider in the 75th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$70,819
Medicare patients
132
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$108,301
TrintellixVortioxetine Hydrobromide11$5,042
Bupropion XlBupropion Hcl118$2,710
Quetiapine Fumarate108$1,723
Desvenlafaxine Succinate ErDesvenlafaxine Succinate33$1,363
Aripiprazole26$1,308
Lamotrigine34$1,254
Duloxetine Hcl47$1,080
Olanzapine39$1,061
Zolpidem Tartrate ErZolpidem Tartrate11$979
Alprazolam99$862
Sertraline Hcl66$858
Divalproex Sodium ErDivalproex Sodium23$749
Lorazepam74$700
Clorazepate Dipotassium11$672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$302$108,30113 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$180$5,04211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →